Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) cells ISB 2301 is rapidly advancing toward the clinic; ...
NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 /PRNewswire/ -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today ...
In an upshot for Indian innovation, drugmaker Glenmark Pharmaceutical’s wholly-owned subsidiary Ichnos Glenmark Innovation Inc (IGI) has signed an exclusive licensing agreement with US drugmaker ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results